First Allied Advisory Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

First Allied Advisory Services’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,430	Closed	-$517K	–	1160
2015 Q2	$517K	Buy	+6,430	New	+$419K	0.02%	611
2014 Q2	–	Sell	-10,600	Closed	-$134K	–	1077
2014 Q1	$134K	Buy	+10,600	New	+$144K	0.01%	934

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

First Allied Advisory Services's EGRX Position: Q3 2015 in Review

First Allied Advisory Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2015, closing a stake of 6,430 shares — an estimated $517K sold.

First Allied Advisory Services first reported a position in EGRX in Q1 2014 and held it in 2 quarters. The position peaked at $517K in Q2 2015. 119 funds tracked by Wall St. Rank hold EGRX as of Q3 2015.

First Allied Advisory Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
First Allied Advisory Services sold 6,430 Eagle Pharmaceuticals, Inc. shares in Q3 2015, an estimated $517K.
First Allied Advisory Services first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 2 quarters.
First Allied Advisory Services's Eagle Pharmaceuticals, Inc. position peaked at $517K in Q2 2015.
119 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2015.

Based on First Allied Advisory Services's 13F filing for Q3 2015, filed 12 Nov 2015.